Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Consolidated Net Income (2023 - 2025)

Historic Consolidated Net Income for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' Consolidated Net Income rose 1962.43% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 10943.65%. This contributed to the annual value of $1.7 billion for FY2024, which is 80395.57% up from last year.
  • Inhibrx Biosciences' Consolidated Net Income amounted to -$35.3 million in Q3 2025, which was up 1962.43% from -$28.7 million recorded in Q2 2025.
  • Inhibrx Biosciences' Consolidated Net Income's 5-year high stood at $1.9 billion during Q2 2024, with a 5-year trough of -$92.0 million in Q4 2023.
  • For the 3-year period, Inhibrx Biosciences' Consolidated Net Income averaged around $139.0 million, with its median value being -$45.5 million (2023).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first surged by 404884.6% in 2024, then plummeted by 10154.22% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Consolidated Net Income stood at -$92.0 million in 2023, then soared by 47.96% to -$47.9 million in 2024, then grew by 26.34% to -$35.3 million in 2025.
  • Its Consolidated Net Income stands at -$35.3 million for Q3 2025, versus -$28.7 million for Q2 2025 and -$43.3 million for Q1 2025.